Journal-Clubbing Our Way Through Internal Medicine
Do you also find it hard to follow the medical literature?
Newsletters with tables of contents are hard to get through after having written all your notes and maybe having done a chart dissection.
Welcome to IM Journal Club!
Our mission: to guide you through some of the most interesting internal medicine studies published in the last few weeks and months that you WOULD have liked to or SHOULD have heard about
Target groups: physicians and other clinicians in general internal or family medicine – hospital medicine and primary care – or in an internal medicine subspecialty; biostatisticians, epidemiologists, or data scientists; journal club enthusiasts!
Hidden agenda: to shed some lights on the studies’ methods AND on the context (what was known before, how do the new results change things – so what does this all mean?). We will give you episodes with primers on particularly difficult methods.
We will come out with a new episode every one to two weeks - we'll upload early on Fridays - so you can listen on your commute or on the weekend.
Please subscribe in your favorite podcast app or to our YouTube channel .
Please let us know what we can do better, or what new study we could cover: You can leave a review in your podcasting app, a comment on YouTube, or drop us a line at hello@imjournalclub.com
We are also on social; our email newsletter will be on Twitter: https://twitter.com/IMJournalClub
---
Show Credits
Host: Ben Geisler
Video editor: Fernando Tábora
Methods consultant: Professor Ulrich Mansmann
Advisory group (current): Bijay Acharya, Chang-Berm Kang, Jeffrey L. Greenwald, Jonathan W. Heflin, Kathy May Tran, Marcel Müller, Rahul Ganatra, and Warren Chuang
Supported by LMU Munich’s Institute for Epidemiology, Biometry, and Medical Information Processing
Hosted on Acast. See acast.com/privacy for more information.
Journal-Clubbing Our Way Through Internal Medicine
Do you also find it hard to follow the medical literature?
Newsletters with tables of contents are hard to get through after having written all your notes and maybe having done a chart dissection.
Welcome to IM Journal Club!
Our mission: to guide you through some of the most interesting internal medicine studies published in the last few weeks and months that you WOULD have liked to or SHOULD have heard about
Target groups: physicians and other clinicians in general internal or family medicine – hospital medicine and primary care – or in an internal medicine subspecialty; biostatisticians, epidemiologists, or data scientists; journal club enthusiasts!
Hidden agenda: to shed some lights on the studies’ methods AND on the context (what was known before, how do the new results change things – so what does this all mean?). We will give you episodes with primers on particularly difficult methods.
We will come out with a new episode every one to two weeks - we'll upload early on Fridays - so you can listen on your commute or on the weekend.
Please subscribe in your favorite podcast app or to our YouTube channel .
Please let us know what we can do better, or what new study we could cover: You can leave a review in your podcasting app, a comment on YouTube, or drop us a line at hello@imjournalclub.com
We are also on social; our email newsletter will be on Twitter: https://twitter.com/IMJournalClub
---
Show Credits
Host: Ben Geisler
Video editor: Fernando Tábora
Methods consultant: Professor Ulrich Mansmann
Advisory group (current): Bijay Acharya, Chang-Berm Kang, Jeffrey L. Greenwald, Jonathan W. Heflin, Kathy May Tran, Marcel Müller, Rahul Ganatra, and Warren Chuang
Supported by LMU Munich’s Institute for Epidemiology, Biometry, and Medical Information Processing
Hosted on Acast. See acast.com/privacy for more information.
Before and after molnupiravir/ritonavir (Paxlovid(R)), there have been monoclonal antibodies and other antivirals. However, molnupiravir/ritonavir can be taken orally and might have a high effectiveness in preventing severe COVID-19 for those at an increased risk for it. We discuss the recently published EPIC-HR study as well as the broader implications.
0:00 Intro
2:01 Pax Romana
2:44 Outpatient Options for Early Treatment to Prevent Hospitalization
6:03 PF-0731332 (nirmatrelvir)
8:33 Paxlovid (Nirmatrelvir-Ritonavir)
10:12 Research on Nirmatrelvir
11:18 The EPIC-HR Study
13:37 Author Affiliations
14:03 Inclusion and exclusion criteria
15:36 Results with subgroup analysis
19:27 Should we believe Paxlovid results?
21:15 Can Paxlovid be used in our patients?
22:35 Absolute contra-indications
23:25 Relative contra-indications
24:52 Should we use Paxlovid over others?
28:01 Can we use Paxlovid for ourselves?
29:11 Summary: Paxlovid Utility
31:00 What's next for Paxlovid?
32:38 Paxlovid Romana?
33:54 Q&A
Speaker: Warren Chuang, MD, MA; Massachusetts General Hospital/Harvard Medical School
Recording date: May 19,2022
Ref: Hammond J et al. N Engl J Med 2022; 386:1397-1408 doi: 10.1056/NEJMoa2118542
#paxlovid #covid19 #treatment
Hosted on Acast. See acast.com/privacy for more information.